Nature’s Sunshine Products, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing, not a standalone fourth-quarter report; selected Q4 results are included below. The company manufactures and sells nutritional and personal-care products primarily through independent consultants across four geographic segments.
Financial performance
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net sales | $444.1 million | $385.2 million |
| Gross profit / margin | $328.6 million / 74.0% | $283.9 million / 73.7% |
| Operating income / margin | $34.7 million / 7.8% | $21.5 million / 5.6% |
| Net income | $30.2 million | $23.0 million |
| Net income attributable to common shareholders | $28.9 million; diluted EPS $1.42 | $21.3 million; diluted EPS $1.07 |
| Operating cash flow | $34.6 million | $37.7 million |
Sales grew 15.3% reported and 13.6% excluding currency effects. Sales by segment were Asia $176.9 million (+27.5%), Europe $91.5 million (+17.8%), North America $149.7 million (+2.9%), and Latin America and Other $25.9 million (+11.2%). Gross margin improved, while SG&A rose $22.8 million to $154.1 million, or 34.7% of sales. Volume incentives declined to 31.5% of sales from 34.0%.
Q4 2021: Net sales were $117.9 million versus $101.7 million in Q4 2020; operating income was $7.5 million versus $2.2 million. Net income attributable to common shareholders was $13.4 million versus $5.9 million. Q4 2021 included an income tax benefit of $6.8 million, a significant contributor to reported quarterly net income.
Liquidity, debt and capital allocation
- Year-end cash and cash equivalents were $86.2 million, including $67.7 million held by foreign subsidiaries and potentially subject to repatriation restrictions or withholding taxes. Working capital was $88.0 million, up from $84.4 million.
- Operating cash flow was $34.6 million; capital expenditures were $6.7 million. Management attributed lower operating cash flow versus 2020 mainly to inventory investment and the timing of receivable collections.
- No balance was drawn on the $25.0 million revolving credit facility; $2.4 million remained outstanding under equipment financing. The company reported compliance with debt covenants.
- Financing activities used $31.7 million, including a one-time $19.9 million special dividend and $7.4 million of share repurchases. The repurchase program had $7.6 million remaining at year-end.
Changes, outlook and risks
- Growth occurred in all segments, led by Asia. Management cited demand for nutritional supplements, promotions and consultant engagement initiatives. North America’s increase was more modest.
- Foreign-exchange losses were $3.1 million in 2021, compared with gains of $1.3 million in 2020. The effective tax rate was 5.1%, compared with a 0.6% tax benefit in 2020; the 2021 rate reflected, among other items, a reduction in valuation allowances.
- Advertising expense increased to $8.2 million from $1.8 million as the company pursued brand-building efforts. Restructuring expenses were $0.4 million in 2021, following $0.8 million in 2020.
- The filing provides no specific quantified revenue or earnings guidance. Management said operating cash, available cash and credit availability should cover normal operating needs, while noting that downturns, weaker demand, tax outcomes and other contingencies could harm liquidity.
- Key exposures include consultant recruitment and retention, direct-selling and product-claim regulation, product liability, CBD regulation, supply-chain and transportation constraints, COVID-19 disruption, currency movements, China joint-venture and regulatory risks, cybersecurity, and tax and transfer-pricing matters.
- Subsequent event: The filing describes Russia’s February 2022 invasion of Ukraine and says the impact could not then be estimated. Russia and Other generated $61.4 million of 2021 net sales and $5.8 million of operating income; year-end assets were $6.8 million.
- Non-income-tax contingencies were accrued at $0.2 million, with possible future payments estimated at $0–$2.6 million. Other litigation had $0.5 million accrued, with possible payments estimated at $0–$0.4 million; outcomes remain uncertain.
The auditor issued an unqualified opinion on the financial statements and internal control over financial reporting. The valuation of deferred tax assets was identified as a critical audit matter.
Important facts for investors to verify
- How much of 2021 growth and margin improvement is sustainable, particularly in Asia and China, and how much depended on promotions, market mix or pandemic-era demand.
- The effect of Russia–Ukraine conflict, sanctions, currency movements and possible business interruptions on sales, earnings, cash access and assets in the region.
- Whether higher SG&A and advertising spending can support continued growth without eroding operating margins.
- The quality and recoverability of the increased inventory balance ($60.9 million versus $47.7 million) and the potential for further supply-chain costs or obsolescence.
- The assumptions behind deferred tax asset recoverability, valuation allowances and the low 2021 effective tax rate, as well as the status of tax and other contingencies.